• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.新型肽类抗生素短杆菌肽与万古霉素、替考拉宁和达托霉素的活性比较。
Antimicrob Agents Chemother. 1991 May;35(5):998-1000. doi: 10.1128/AAC.35.5.998.
2
In vitro activity of the new glycopeptide decaplanin.
Eur J Clin Microbiol Infect Dis. 1992 May;11(5):458-62. doi: 10.1007/BF01961864.
3
In vitro activity of LY264826 compared to other glycopeptides and daptomycin.LY264826与其他糖肽类抗生素和达托霉素的体外活性比较。
Diagn Microbiol Infect Dis. 1991 Mar-Apr;14(2):181-4. doi: 10.1016/0732-8893(91)90056-l.
4
In vitro activity of LY146032 (daptomycin), a new peptolide.新型缩酚肽LY146032(达托霉素)的体外活性
Eur J Clin Microbiol. 1987 Feb;6(1):84-90. doi: 10.1007/BF02097208.
5
In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates.默克西丁(M87-1551)的体外活性,一种针对革兰氏阳性血流分离株进行测试的研究性肽类抗生素。
Diagn Microbiol Infect Dis. 1992 Sep-Oct;15(7):641-4. doi: 10.1016/0732-8893(90)90043-u.
6
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.
7
Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.新型脂肽类抗菌药物LY146032(达托霉素)的体外活性比较
Eur J Clin Microbiol. 1987 Feb;6(1):100-3. doi: 10.1007/BF02097211.
8
In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.万古霉素和替考拉宁对厌氧菌的体外活性。
Drugs Exp Clin Res. 1987;13(9):551-4.
9
Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.达托霉素和替考拉宁对溶血葡萄球菌和表皮葡萄球菌的活性,包括药敏试验建议的评估。
Antimicrob Agents Chemother. 1989 Apr;33(4):585-8. doi: 10.1128/AAC.33.4.585.
10
In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.达托霉素(LY146032)和帕地霉素(U-70,138F)对厌氧革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 1988 May;32(5):788-90. doi: 10.1128/AAC.32.5.788.

引用本文的文献

1
Effect of Bacillus velezensis MT9 on Nile Tilapia (Oreochromis Niloticus) Intestinal Microbiota.解淀粉芽孢杆菌MT9对尼罗罗非鱼(尼罗罗非鱼)肠道微生物群的影响。
Microb Ecol. 2025 May 1;88(1):37. doi: 10.1007/s00248-025-02531-2.
2
Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment for Infections in Animals and Humans.评估细菌素作为动物和人类感染替代治疗方法的转化潜力。
Antibiotics (Basel). 2023 Jul 30;12(8):1256. doi: 10.3390/antibiotics12081256.
3
Class II two-peptide lanthipeptide proteases: exploring LicTP for biotechnological applications.II 类双肽类蓝细菌肽酶:探索 LicTP 用于生物技术应用。
Appl Microbiol Biotechnol. 2023 Mar;107(5-6):1687-1696. doi: 10.1007/s00253-023-12388-5. Epub 2023 Feb 10.
4
Aminovinyl Cysteine Containing Peptides: A Unique Motif That Imparts Key Biological Activity.含氨基乙烯基半胱氨酸的肽:赋予关键生物活性的独特基序。
JACS Au. 2021 Sep 15;1(10):1527-1540. doi: 10.1021/jacsau.1c00308. eCollection 2021 Oct 25.
5
Bacteriocins: Potential for Human Health.细菌素:对人类健康的潜在影响。
Oxid Med Cell Longev. 2021 Apr 10;2021:5518825. doi: 10.1155/2021/5518825. eCollection 2021.
6
Bacteriocins, Antimicrobial Peptides from Bacterial Origin: Overview of Their Biology and Their Impact against Multidrug-Resistant Bacteria.细菌素:源自细菌的抗菌肽——其生物学特性及对多重耐药菌影响的概述
Microorganisms. 2020 Apr 27;8(5):639. doi: 10.3390/microorganisms8050639.
7
Cell Wall-active Bacteriocins and Their Applications Beyond Antibiotic Activity.细胞壁活性细菌素及其抗生素活性之外的应用
Probiotics Antimicrob Proteins. 2012 Dec;4(4):259-72. doi: 10.1007/s12602-012-9116-9.
8
Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria.脂质II靶向抗菌剂乳链菌肽、Lacticin 3147和万古霉素对革兰氏阳性菌的效力比较。
Probiotics Antimicrob Proteins. 2012 Jun;4(2):108-15. doi: 10.1007/s12602-012-9095-x.
9
Bioengineering Lantibiotics for Therapeutic Success.用于治疗成功的生物工程羊毛硫抗生素。
Front Microbiol. 2015 Nov 27;6:1363. doi: 10.3389/fmicb.2015.01363. eCollection 2015.
10
Bacteriocins - a viable alternative to antibiotics?细菌素——抗生素的可行替代品?
Nat Rev Microbiol. 2013 Feb;11(2):95-105. doi: 10.1038/nrmicro2937. Epub 2012 Dec 24.

本文引用的文献

1
Method of reliable determination of minimal lethal antibiotic concentrations.可靠测定最低致死抗生素浓度的方法。
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
2
Coagulase-negative staphylococci. Epidemiology, evaluation, and therapy.凝固酶阴性葡萄球菌。流行病学、评估与治疗。
Infect Dis Clin North Am. 1989 Dec;3(4):915-29.
3
Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures.耐甲氧西林金黄色葡萄球菌。检测、流行病学及控制措施。
Infect Dis Clin North Am. 1989 Dec;3(4):901-13.
4
The epidemiology of enterococci.肠球菌的流行病学
Eur J Clin Microbiol Infect Dis. 1990 Feb;9(2):80-9. doi: 10.1007/BF01963631.

新型肽类抗生素短杆菌肽与万古霉素、替考拉宁和达托霉素的活性比较。

Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.

作者信息

Niu W W, Neu H C

机构信息

Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York 10032.

出版信息

Antimicrob Agents Chemother. 1991 May;35(5):998-1000. doi: 10.1128/AAC.35.5.998.

DOI:10.1128/AAC.35.5.998
PMID:1649577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC245145/
Abstract

Mersacidin, a new peptide antibiotic, was four- to eightfold less active (MIC for 90% of isolates, 8 micrograms/ml) than vancomycin, teicoplanin, or daptomycin against Staphylococcus aureus. Coagulase-negative staphylococci were inhibited by 8 micrograms/ml, and the MICs of mersacidin for hemolytic streptococci and Streptococcus pneumoniae were 4 to 8 micrograms/ml. The mersacidin MICs for anaerobic organisms were as follows: Clostridium perfringens, 4 micrograms/ml; Propionibacterium acnes, 8 micrograms/ml; peptococci, 1 microgram/ml; and peptostreptococci, 8 micrograms/ml. Mersacidin had no activity against members of the family Enterobacteriaceae, Neisseria and Haemophilus species, or Pseudomonas aeruginosa. The size of the inoculum, the pH of the assay (5.5 to 7.5), the type of medium, and the anaerobic conditions had minimal effects on the MICs and MBCs of mersacidin. Overall, mersacidin proved less active than available glycopeptides and peptolides.

摘要

新型肽类抗生素梅萨西丁对金黄色葡萄球菌的活性比万古霉素、替考拉宁或达托霉素低4至8倍(90%分离株的MIC为8微克/毫升)。凝固酶阴性葡萄球菌被8微克/毫升抑制,梅萨西丁对溶血性链球菌和肺炎链球菌的MIC为4至8微克/毫升。梅萨西丁对厌氧菌的MIC如下:产气荚膜梭菌为4微克/毫升;痤疮丙酸杆菌为8微克/毫升;消化球菌为1微克/毫升;消化链球菌为8微克/毫升。梅萨西丁对肠杆菌科、奈瑟菌属和嗜血杆菌属成员或铜绿假单胞菌无活性。接种物大小、测定pH值(5.5至7.5)、培养基类型和厌氧条件对梅萨西丁的MIC和MBC影响极小。总体而言,梅萨西丁的活性低于现有的糖肽类和肽醇类药物。